Renal protective role of bradykinin B1 receptor in stroke-prone spontaneously hypertensive rats

Hypertension Research

Volumn 27, Issue 6, 2004, Pages 399-408

  Hagiwara, Makoto ^a   Murakami, Hideyuki ^a   Ura, Nobuyuki ^a   Agata, Jun ^a   Yoshida, Hideaki ^a   Higashiura, Katsuhiro ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bradykinin B1 receptor; Hypertension; Kidney; NOx; Stroke prone spontaneously hypertensive rats

Indexed keywords

BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ B1 RECEPTOR ANTAGONIST; COLLAGEN TYPE 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME PHOSPHORYLATION; ESSENTIAL HYPERTENSION; GLOMERULUS; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY TUBULE; MALE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RAT; RAT STRAIN; RECEPTOR UPREGULATION; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; HYPERTENSION, RENAL; KALLIKREIN-KININ SYSTEM; KIDNEY CORTEX; MALE; NITROGEN COMPOUNDS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, BRADYKININ B1; RNA, MESSENGER;

EID: 3242886689     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.399     Document Type: Article

References (47)

1. Bhoola KD, Figueroa CD, Worthy K: Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1-80.
2. Margolius HS: Theodore Cooper Memorial Lecture: kallikreins and kinins: some unanswered questions about system characteristics and roles in human disease. Hypertension 1995; 26: 221-229.
3. Iimura O, Shimamoto K, Ura N, et al: Study on the renal kallikrein-kinin system in normal and low renin subgroups of essential hypertension. J Hypertens 1984; 2: S297-S299.
4. Shimamoto K, Ura N, Ishiguro T, Nakagawa M, Iimura O: The role of renal natriuretic depressor systems on hypertensive mechanisms in reduced renal mass hypertensive rats. Hypertens Res 1995; 18: S53-S57.
5. Iimura O, Ura N, Nakagawa M: Comparative hypertensionology-renal dopaminergic activity in experimental hypertensive rats. Clin Exp Hypertens 1997; 19: 117-130.
6. Yoshida H, Nakagawa M, Aoyama T, et al: Urinary kallikrein in Dahl-Iwai salt-sensitive and -resistant rats. Am J Hypertens 1997; 10: S73-S77.
7. Hirawa N, Uehara Y, Suzuki T, et al: Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event. Nephron 1999; 81: 183-193.
8. Chao J, Chao L: New experimental evidence for a role of tissue kallikrein in hypertension. Nephrol Dial Transplant 1997; 12: 1569-1574.
9. Murakami H, Yayama K, Chao L, Chao J: Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int 1998; 53: 1305-1313.
10. Chao J, Zhang JJ, Lin KF, Chao L: Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 1998; 9: 21-31.
11. Wolf WC, Yoshida H, Agata J, Chao L, Chao J: Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 2000; 58: 730-739.
12. McLean PG, Perretti M, Ahluwalia A: Kinin B1 receptors and the cardiovascular system: regulation of expression and function. Cardiovasc Res 2000; 48: 194-210.
13. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H: Vasoactive potential of the B(1) bradykinin receptor in normotension and hypertension. Circ Res 2001; 88: 275-281.
14. Marin-Castano ME, Schanstra JP, Neau E, et al: Induction of functional bradykinin B(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 2002; 105: 627-632.
15. Kwon TH, Nielsen J, Masilamani S, et al: Regulation of collecting duct AQP3 expression: response to mineralocorticoid. Am J Physiol Renal Physiol 2002; 283: F1403-F1421.
16. Wotherspoon G, Winter J: Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system. Neurosci Lett 2000; 294: 175-178.
17. Furuhashi M, Ura N, Murakami H, et al: Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J Endocrinol 2002; 174: 321-329.
18. Ni A, Chai KX, Chao L, Chao J: Molecular cloning and expression of rat bradykinin B1 receptor. Biochim Biophys Acta 1998; 1442: 177-185.
19. McEachern AE, Shelton ER, Bhakta S, et al: Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci USA 1991; 88: 7724-7728.
20. Haslett JN, Sanoudou D, Kho AT, et al: Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci U S A 2002; 99: 15000-15005.
21. Spillmann F, Altmann C, Scheeler M, et al: Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy. Int Immunopharmacol 2002; 2: 1823-1832.
22. Agata J, Miao RQ, Yayama K, Chao L, Chao J: Bradykinin B(1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension 2000; 36: 364-370.
23. Marin-Castano ME, Schanstra JP, Praddaude F, et al: Differential induction of functional B1-bradykinin receptors along the rat nephron in endotoxin induced inflammation. Kidney Int 1998; 54: 1888-1898.
24. Regoli DC, Marceau F, Lavigne J: Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol 1981; 71: 105-115.
25. McLean PG, Perretti M, Ahluwalia A: Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9-bradykinin-induced coronary vasodilation. Br J Pharmacol 1999; 128: 275-282.
26. Schnackenberg CG, Wilcox CS: Two-week administration of tempol attenuates both hypertension and renal excretion of 8-iso prostaglandin f2alpha. Hypertension 1999; 33: 424-428.
27. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC: Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001; 37: 781-786.
28. Schanstra JP, Marin-Castano ME, Praddaude F, et al: Bradykinin B(1) receptor-mediated changes in renal hemodynamics during endotoxin-induced inflammation. J Am Soc Nephrol 2000; 11: 1208-1215.
29. Siebeck M, Whalley ET, Hoffmann H, Weipert J, Fritz H: The hypotensive response to des-Arg9-bradykinin increases during E. coli septicemia in the pig. Adv Exp Med Biol 1989; 247: 389-393.
30. Nakhostine N, Ribuot C, Lamontagne D, Nadeau R, Couture R: Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br J Pharmacol 1993; 110: 71-76.
31. Emanueli C, Chao J, Regoli D, Chao L, Ni A, Madeddu P: The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. Br J Pharmacol 1999; 126: 1769-1776.
32. Ni A, Yin H, Agata J, Yang Z, Chao L, Chao J: Overexpression of kinin B1 receptors induces hypertensive response to Des-Arg9-bradykinin and susceptibility to inflammation. J Biol Chem 2003; 278: 219-225.
33. Pesquero JB, Araujo RC, Heppenstall PA, et al: Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci USA 2000; 97: 8140-8145.
34. Conklin BR, Burch RM, Steranka LR, Axelrod J: Distinct bradykinin receptors mediate stimulation of prostaglandin synthesis by endothelial cells and fibroblasts. J Pharmacol Exp Ther 1988; 244: 646-649.
35. Cahill M, Fishman JB, Polgar P: Effect of des arginine9-bradykinin and other bradykinin fragments on the synthesis of prostacyclin and the binding of bradykinin by vascular cells in culture. Agents Actions 1988; 24: 224-231.
36. Wirth KJ, Scholkens BA, Wiemer G: The bradykinin B2 receptor antagonist WIN 64338 inhibits the effect of des-Arg9-bradykinin in endothelial cells. Eur J Pharmacol 1994; 288: R1-R2.
37. Wiemer G, Wirth K: Production of cyclic GMP via activation of B1 and B2 kinin receptors in cultured bovine aortic endothelial cells. J Pharmacol Exp Ther 1992; 262: 729-733.
38. Marceau F, Larrivee JF, Bouthillier J, Bachvarova M, Houle S, Bachvarov DR: Effect of endogenous kinins, prostanoids, and NO on kinin B1 and B2 receptor expression in the rabbit. Am J Physiol (Lond) 1999; 277: R1568-R1578.
39. Akiba Y, Yamaguchi N, Amano H, et al: Role of nitric oxide in the control of blood pressure in young and adult spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1995; 22: S142-S143.
40. Vaziri ND, Ni Z, Oveisi F: Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension 1998; 31: 1248-1254.
41. Vaziri ND, Ni Z, Oveisi F, Trnavsky-Hobbs DL: Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension 2000; 36: 957-964.
42. Morrissey JJ, Ishidoya S, McCracken R, Klahr S: Nitric oxide generation ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. J Am Soc Nephrol 1996; 7: 2202-2212.
43. Ono H, Ono Y, Takanohashi A, Matsuoka H, Frohlich ED: Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension 2001; 38: 1300-1306.
44. Shihab FS, Yi H, Bennett WM, Andoh TF: Effect of nitric oxide modulation on TGF-beta 1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000; 58: 1174-1185.
45. Tahira Y, Fukuda N, Endo M, et al: Transforming growth factor-beta expression in cardiovascular organs in stroke-prone spontaneously hypertensive rats with the development of hypertension. Hypertens Res 2002; 25: 911-918.
46. Chin BY, Mohsenin A, Li SX, Choi AM, Choi ME: Stimulation of pro-α1(I) collagen by TGF-β1 in mesangeal cells: role of the p38 MAPK pathway. Am J Physiol Renal Physiol 2001; 280: F495-F504.
47. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos EG: Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem 2002; 277: 16847-16852.